Keeping Pace: Advances in First-Line Therapy for RET Fusion-Positive NSCLC

Keeping Pace: Advances in RET Fusion-Positive NSCLC

Keeping Pace: Advances in RET Fusion-Positive NSCLC
RestartResume

How can you implement the rapidly changing recommendations for RET Fusion-Positive NSCLC therapy into your clinical practice?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice.

    Since this CME activity has been published the FDA has approved a new treatment for adults with metastatic RET fusion-positive non-small cell lung cancer. To learn more about this approval, please visit the FDA.gov: FDA approves pralsetinib for lung cancer with RET gene fusions

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mark A. Socinski, MD
    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL

    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novartis
    Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Faculty:
    Alexander Drilon, MD
    Chief, Early Drug Development
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees: 14ner/Elevation Oncology, Abbvie, ArcherDX, AstraZeneca, BeiGene, BerGenBio, Blueprint Medicines, EMD Serono, Exelixis, Faculty RTP, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Medendi, MJH, Monopteros, MORE Health, Novartis, Pfizer, Remedica Ltd, Roche, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, Verastem
    Contracted Research: Exelixis, Foundation Medicine, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, Teva
    Royalties: Wolters Kluwer

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • William A. Mencia, MD, has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • The Postgraduate Institute for Medicine planners and managers have nothing to disclose.
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Apply best practices to guide first-line treatment selection for RET fusion-positive NSCLC based on the presence or absence of specific actionable mutations.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pulmonologists, pathologists, nurses, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Learning Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.025 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2265-H01-P)

    ACPE release date: 8/31/2020
    ACPE expiration date: 8/31/2021

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    Joint provided by Global Learning Collaborative and Postgraduate Institute for Medicine.

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Myers Squibb, Lilly, and Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free